New inflammation inhibitor could treat sepsis

Image
IANS London
Last Updated : Nov 18 2018 | 6:35 PM IST

Researchers have developed an anti-inflammatory drug molecule that could lead to better treatments for diseases such as sepsis and potentially other autoimmune diseases.

"We've developed a new drug molecule that inhibits inflammation," said lead author of the study Thomas Helleday from Karolinska Institutet in Sweden.

The discovery is the result of many years of research by Helleday's group on how DNA is repaired by the body.

It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation.

It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.

The inhibitor blocks the release of inflammatory proteins, such as TNF alpha, said the study published in the journal Science.

In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.

The researchers found that the inhibitor works in a way which is different from other anti-inflammatory drugs currently available and could also help to prevent our own immune system attacking itself in conditions such as sepsis, multiple sclerosis, crohn's disease and potentially other autoimmune disorders.

Inflammation is a process where the body's white blood cells protect us from infection, such as bacteria and viruses.

However, in some conditions the immune system triggers an inflammatory response when there is no infection to fight off. This causes the body's normally protective immune system to cause damage to its own tissues.

"When oxygen regulation in our cells goes wrong it can cause damage to our DNA and trigger our immune system to responding," said Helleday who is also affiliated with University of Sheffield in Britain.

"Our immune system is our defence mechanism which normally fights off invasion from bacteria and viruses, however sometimes it can misfire and attack our own bodies.

"Isolating an inhibitor which can switch this response off is a major breakthrough and we are really excited about developing our research to see if we can not only decrease existing inflammation in other areas of the body, but prevent inflammation altogether.

"This would pave the way for new, effective treatments for life-threatening diseases like sepsis," Helleday said.

--IANS

gb/sed

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 18 2018 | 6:28 PM IST

Next Story